PURPOSE: Blood platelet activity increases with advancing age. This study was designed to deterThine if changes in a key signal-transducing mechanism in the platelet, phosphoinositide turnover, are associated with the enhanced platelet activity seen in aging.
PURPOSE: Blood platelet activity increases with advancing age. This study was designed to deterThine if changes in a key signal-transducing mechanism in the platelet, phosphoinositide turnover, are associated with the enhanced platelet activity seen in aging.
PATIENTS AND METHODS: Piatelets were harvested from a total of 40 healthy, non-obese, 22-to 62-year-old individneln, free of any clinical evidence of atherosclerotic vascular disease, and having normal serum laboratory lipid levels. Studies of platelet activity included measurement of/n vitro piatelet aggregation and plasma #-thrombeglobulin (~-TBG), a m~rker of/n vivo platelet secretion. Basal and thrombin-stimulated phosphoinositide turnover was measured following [32p]-orthophosphate incorporation into the various phospholipids, isolation of the phosphoinositides and phosphatidic acid by thin-iayer chromatography and autoradiography, and quantification by liquid scintillation spectroscopy of these radioiabeled phospholipids.
RESULTS: There was a positive correlation with age for both adenosine diphosphate (ADP)-induced aggregation (L25 #M, r = 0.464, p <0.001; 2.5 #M, r = 0.386, p <0.05) and plasma #-TBG (r = 0.381, p <0.055). There was a time-dependent increase of
[32p]orthophosphate (32Pi) incorporation into piatelet phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 4-phosphate (PIP), and isotopic equilibrium was reached by 120 minutes at 37°C. A positive correlation was found between age and basal 32p-PIP2 (r = 0.640, p <0.001) and 32p-PIP (r = 0.676, p <0.0005). Basal 32p i incorporation into PIP2 correlated positively with/n vitro aggregation (1.25 #M ADP, r = 0.795, p <0.0001; 2.5 #M ADP, r = 0.755, p <0.0005) as did 32p i incorporation into PIP (1.25 #M ADP, r = 0.815, p <0.0001; 2.5 #M ADP, r = 0.795, p <0.0001). There was also a positive correlation between plasma ~-TBG levels and basal 32p. PIP2 (r = 0.768, p <0.005) and 32p-PIP (r = 0.505, p <0.066). Finally, increasing age correlated with thrombin (4 U/mL)-stimulated 32p-PIP2 hydrolysis (r = 0.694, p <0.01) and phosphatidic acid formation (r = 0.556, p <0.05).
CONCLUSION: Advancing age is associated with an increase in/n vitro piatelet aggregation, elevated ~-TBG levels, and enhanced phosphoinositide turnover. Because phosphoinositide turnover is associated with stimulus-coupled platelet activation, the increased basal and stimulated phosphoinositide turnover may mediate the increase in piatelet activity with aging.
A n increase in platelet aggregability has been proposed as a contributing factor to the development of atherosclerotic vascular disease [1] . Advancing age is associated with both atherosclerosis and platelet hyperaggregation [2] . Increased in vitro platelet aggregatory responses to adenosine diphosphate (ADP) with increasing age have been reported [3] . Plasma levels of ~-thromboglobulin (~-TBG) (a platelet-specific protein secreted upon activation) increase with age and have been correlated with platelet hyperaggregation [4] . Biochemical mechanisms associated with the in vitro and in vivo increases in platelet activity with aging are not known.
Platelet activation is associated with phosphoinositide turnover and formation of second messengers 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) from hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) [5] [6] [7] [8] [9] . DAG is rapidly phosphorylated by a DAG kinase to form phosphatidic acid (PA). Calcium mobilization, protein kinase C activation, and platelet alpha and dense granule secretion are linked to formation of these second messengers [9, 10] . The impact of aging on phosphoinositide turnover is not known.
In the present study, we have examined the hypothesis that advancing age enhances ADP-induced aggregation and raises plasma ~-TBG as a function of platelet phosphoinositide content and turnover. We confirm here the previous findings that in vitro ADPinduced aggregation and in vivo plasma B-TBG increase with advancing age. We demonstrate that platelet polyphosphoinositide content correlates with both age and ADP-induced aggregation. Furthermore, upon platelet stimulation with thrombin, PIP2 hydrolysis and PA generation increase as a function of increasing age. We suggest that the increase in in vitro platelet aggregation and raised plasma/~-TBG levels that occur with advancing age are due to an increase in basal and stimulated platelet phosphoinositide turnover.
PATIENTS AND METHODS
A total of 40 healthy 22-to 62-year-old volunteers (21 men and 19 women) free of any clinical disease, including evidence of atherosclerotic vascular disease, were recruited for the study. None of the volunteers were obese, and all had serum cholesterol, triglyceride, creatinine, and fasting glucose levels within the normal laboratory range. The subjects were instructed to take no medications specifically known to affect platelet function for at least 1 week before the study. Blood sampling was performed at the same early morning hour (8 A.M.) after at least a 12-hour fast. Informed written consent was obtained from each volunteer. The study was approved by the Institutional Review Board Human Use Committee at the University of Michigan Medical Center.
In vitro platelet aggregation was performed by a turbidometric technique similar to that described by Born and Cross [11] . Forty milliliters of whole blood were gently dispersed into a polypropylene tube containing 3.5% trisodium citrate anticoagulant (9:1, volume:volume [v:v] ) and centrifuged in a swinging bucket rotor at 125 × G for 12 minutes at 22°C. The platelet-rich plasma (PRP) was removed to within 1 cm of the buffy coat. The remaining blood was centrifuged at 5,000 × G for 12 minutes at 22°C and the platelet-poor plasma (PPP) removed (less than 100 platelets per ~L). The platelet count was adjusted to 300,000/~L with autologous PPP using an electronic particle counter. Aliquots (450 #L) of PRP were incubated at 37°C for 2 minutes with constant stirring at 1,200 revolutions/minute and the light transmittance was monitored using an aggregometer. Aggregation was measured on a strip chart recorder in mV and expressed as a percentage of light transmittance of the PPP. For each aggregation curve, percent aggregation was measured with the light transmittance of PPP representing 0% and the light transmittance of the PRP representing 100%. Aggregation studies were completed within 3 hours of obtaining samples. Percent aggregation was measured during primary aggregation at 30, 60, and 120 seconds following the addition of 1.25 and 2.5 ~M ADP. To verify that the platelet release reaction did not occur, adenosine triphosphate (ATP) release from platelet dense-granules was monitored with the luciferin-luciferase reaction by a modification of methods previously described [12] .
In vivo platelet activity was determined by measuring plasma levels of 13-TBG, a protein secreted from platelet alpha-granules upon activation [13] . Triplicate 2.5-mL samples of whole blood were placed in plastic tubes on ice containing 150 ~L of 134 mM EDTA and 15 mM theophylline, and/~-TBG was assayed by radioimmunoassay in the Ligand Laboratory of the Diabetes Research and Training Center at the University of Michigan Medical Center.
Platelet phosphoinositide and PA determinations were carried out by slight modifications of methods established in the literature [14] . Two hundred fifty milliliters of PRP were obtained by plasmapheresis from whole blood collected in an acid/citrate/dextrose anticoagulant buffer (71 mM citric acid, 85 mM trisodium citrate, 111 mM dextrose, pH 5.5, 5:1 v:v). The PRP was centrifuged twice in a swinging bucket rotor at 100 × G for 12 minutes at 22°C to remove any remaining red blood cell contamination. Platelets were pelleted at 1,200 × G for 10 minutes and suspended in a small volume of incubating buffer (20 mM TRIS-HC1, 150 mM sodium chloride, 5 mM glucose, 0.025% bovine serum albumin, pH 7.4) and brought to 2 × 109 platelets/mL with autologous PPP. The final volume of plasma added was 7.5 4-0.4 mL (range of 7.1 to 7.7 mL) with a final phosphorus concentration of 0.8 -1-0.3 mM (range 0.6 to 1.0 raM). Aliquots of 500 #L (1 × 109 platelets) were incubated with 20 #Ci/mL of carrier-free [u2p]orthophosphate (32Pi). After 180 minutes, the incubation was terminated with the addition of phosphate-washing buffer (3.2 mM dipotassium phosphate, 24.4 mM monosodium potassium, 4.2 mM disodium phosphate, 150 mM sodium chloride, 5.5 mM glucose, 0.025% bovine serum albumin, pH 7.4) and then centrifuged at 1,000 × G for 12 minutes. The wash was repeated, the pellet was resuspended in 500 uL TRIS-HC1 pH 7.4 buffer, and the platelet membrane phospholipids were extracted using methanol/ chloroform/hydrochloric acid. The extract was then dried under nitrogen and dissolved in chloroform/ methanol. The extracts were applied to heat-activated oxalate-coated silica plates, and phosphatidylinositol (PI), phosphatidylinositol 4-monophosphate (PIP), PIP2, and PA separated by thin-layer chromatography (TLC) using a Jolles solution [15] . Following TLC and autoradiography, bands were identified and scraped, and the radiolabeled phospholipids were counted by liquid scintillation spectroscopy.
Phosphoinositide turnover and PA formation were also assessed after the addition of thrombin. Aliquots of washed platelets (1 × 109 platelets) were incubated with 20 ~Ci/mL of carrier-free 32Pi for 120 minutes at 37°C. The incubation was terminated with the aforementioned phosphate-washing buffer and then centrifuged at 1,000 × G for 12 minutes. The platelets were suspended in 500 ~L of the aforementioned TRIS-HC1 pH 7.4 buffer and stimulated with 4 U/mL human thrombin. The reaction was terminated with 1.0 mL of cold methanol and chloroform (2:1, v:v). The radiolabeled phospholipids were extracted, isolated by TLC, and quantitated as just described.
The mass of the individual phosphoinositides was estimated using a spectrophotometric assay for phosphorus determination, as previously described [16] . Briefly, the individual radiolabeled phospholipids were extracted from the silica and dephosphorylated with hot magnesium nitrate, and aliquots were added to a malachite green/ammonium molybdate dye solution. Absorbance was read at 660 nm in a light spectrophotometer. Recoveries from silica gel were typically as follows: PA 79%, PIP2 39%, PIP 54%, PI 79%. These are similar to recoveries previously published [17] .
Total serum cholesterol, triglycerides, creatinine, and fasting glucose were determined in the Chemical Pathology Laboratory of the University of Michigan Hospital from samples drawn at the time of platelet testing.
All statistical evaluations were performed on the University of Michigan IBM 3090-600E computer. Simple linear regression, multivariate linear regression, and analysis of covariance were performed where appropriate. Coefficients of correlation (r) were determined by the method of least mean squares. All data are expressed as mean 4-the standard error of the mean. Statistical significance was accepted at the 95% confidence level (p <0.05).
RESULTS
The platelet aggregatory response to both 1.25 ~M and 2.5 #M ADP increased with advancing age (Fig-5O =. == ure 1). In young subjects the percentage aggregation was 10% and 25%, respectively, and increased to 30% and 40% for the two doses of ADP. There was a significant positive correlation between aggregation and age for both 1.25 pM ADP (r = 0.46, p <0.01) and 2.5 #M ADP (r = 0.386, p <0.05). Plasma ~-TBG levels also increased with advancing age. The correlation between plasma ~-TBG and age approached statistical significance (r = 0.381, p <0.055). These studies provide evidence for increased in vitro and in vivo platelet activity. Basal 32Pi incorporation into the phosphoinositides and PA reached isotopic equilibrium by 120 minutes in every subject tested. In the absence of exogenous agonist, the specific activity (32p//~g phosphorus) of PI and PIP2 reached equilibrium at 60 to 90 minutes for PIP2 and between 90 and 120 minutes for PIP ( Figure  2) . Thus, labeling of these polyphosphoinositides with 32Pi for 120 minutes reflects their respective phospholipid mass. Therefore, it was possible to examine the relationship between age and mass of the phosphoinositides. There was a significant positive correlation between basal 32Pi incorporation at 120 minutes into PIP and PIP2 with advancing age (Figure 3) . In addition, the incorporation of 32pi in both phosphoinositides, PIP and PIP2, at the equilibrium time of 120 minutes was found to correlate strongly with the ag- Age (ye=rs) Figure 3 . Relationship between 32P i incorporation into the platelet polyphosphoinositides and age for each individual study subject (n = 25). Top, 32p-PIP versus age, and bottom, 32p-PIP2 versus age. 32pi incorporation into the polyphosphoinositides at 37°C was measured at 120 minutes (see text). The correlation coefficient for linear regression analysis (r) and significance value (p) are given. gregatory response to both 1.25 ~M and 2.5 ~M ADP with correlation coefficients of 0.8 or more and significant levels of p <0.0001 (Figure 4) . It therefore appeared that in vitro aggregation was a function of phosphoinositide turnover.
Since basal 32p incorporation into the polyphosphoinositides would reflect mass of the compounds and not necessarily turnover, the response to activation with thrombin, which is a potent stimulus of platelet phosphoinositide turnover, platelet aggregation, and platelet secretion, was examined. Platelets from 14 subjects were stimulated with 4 U/mL human thrombin, which resulted in a time-dependent increase in 32p-PIP2 hydrolysis and 32p-PA generated when the maximum amount of PIP2 hydrolyzed and PA generated was examined. There was an increase in 32p-PIP2 hydrolysis reflected in decreasing amounts in the PIP2 fraction and increased 32p.pA formation that correlated with advancing age ( Figure 5) .
As a measure of in vivo platelet activation, plasma ~-TBG levels were determined and found to correlate positively with 32p incorporation into both PIP and PIP2, with correlation coefficients of 0.505 (p --0.06) and 0.768 (p <0.005), respectively ( Figure 6 ).
Because platelet activation could reflect changes within the platelet per se or asymptomatic atherosclerotic vascular disease, correlates between in vitro and in vivo aggregation and risk factors for vascular disease were sought. No relationship, however, was found between platelet activation and body mass index, total cholesterol, triglycerides, serum creatinine, or fasting glucose.
COMMENTS
Previous studies have shown that enhanced platelet function is associated with aging in healthy individuals [2] [3] [4] . In the present study, we examined the relationship between aging and platelet function and phosphoinositide turnover, a key regulatory mechanism involved in platelet activation. The present data confirm our preliminary findings [18] , and those of others [19] [20] [21] , of increased in vitro platelet aggregation and increased in vivo platelet activity with aging. Furthermore, we demonstrate that the increased platelet activity with aging is associated with increased basal platelet polyphosphoinositide content and increased thrombin-stimulated platelet phosphoinositide turnover. The increased platelet activity with advancing age is independent of metabolic and hemodynamic perturbations such as those seen in diabetes mellitus and hypertension [22] [23] [24] .
There was a strong positive correlation between age and basal 32pi incorporation at 120 minutes into PIP2 and PI. In addition, 32Pi-labeled polyphosphoinositide content correlated positively with in vitro platelet aggregation and plasma j3-TBG release in these same patients. Since 32Pi labeling was found to reach equilibrium in 120 minutes, tracer was taken to reflect mass, suggesting that polyphosphoinositide content was a major factor in the increased in vitro aggregation and the increased in vivo platelet activity associated with aging. When platelets were stimulated with thrombin, we found a significant positive correlation between age and 3ep-PIP2 hydrolysis and 3ep-PA formation. This provides evidence that age-related increased platelet activity may also be associated with an altered transmembrane signaling mechanism involved in the formation of key intraplatelet second messengers. Because basal levels of PIP and PIP2 correlated with thrombin-stimulated levels of 32p-PIPe and 32P-PA (data not shown), the stimulated hydrolysis of PIP2 may be a function of basal polyphosphoinositide levels.
The importance of age-related changes in the platelet lipid concentration has been studied previously. Particular reference to the arachidonic acid pathway has been emphasized. Prisco et al [25] have shown that platelet lipid composition in healthy 20-to 68-year-old subjects had greater concentrations of cholesterol, an increase in the saturated fatty acid content of phosphatidylcholine, and a decrease in the unsaturated fatty acid content with increasing age. These changes have been associated with enhanced aggregability presumably secondary to increased amounts of thromboxane A2 formation [26, 27] .
Alternatively, decreased levels of linoleic acid and unsaturated fatty acids in the platelet have been implicated as a causal mechanism for increased platelet hypersensitivity in the elderly [28] . Prostaglandin synthesis and cyclooxygenase activity are inhibited by unsaturated fatty acids [29] . It is known that increased thromboxane A2 production and decreased prostacyclin formation occur with advancing age. If arachidonate metabolites were primary to the increased platelet aggregation in aging, it might be expected that inhibition of these pathways in vivo would alter clinical outcome. However, this has not been the case. In the Veterans Administration Cooperative Study, the amputation rate in a group of individuals with peripheral vascular disease receiving aspirin was not different from that in patients treated with placebo [30] . Hence, formation of arachidonate metabolites may not be the 13TG (ng/ml) Figure 6 . Relationship between in vivo platelet activation (determined as plasma fl-TBG) and 32Pi incorporation into the platelet polyphosphoinositides. Top, 32p-PIP versus plasma/~-TBG (n = 29), and bottom, 32p-PIP2 versus plasma/~-TBG (n = 30). Plasma fl-TBG was determined from samples collected at the time platelets were obtained for phosphoinositide turnover and aggregation studies. The correlation coefficient for linear regression analysis (r) and significance value (p) are given.
